25 XP   0   0   10

Jeil Pharm
Buy, Hold or Sell?

Let's analyse Jeil Pharm together

PenkeI guess you are interested in Jeil Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jeil Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jeil Pharm

I send you an email if I find something interesting about Jeil Pharm.

Quick analysis of Jeil Pharm (30 sec.)










What can you expect buying and holding a share of Jeil Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.15
When do you have the money?
1 year
How often do you get paid?
89.3%

What is your share worth?

Current worth
₩26,199.13
Expected worth in 1 year
₩25,052.21
How sure are you?
67.9%

+ What do you gain per year?

Total Gains per Share
₩-928.44
Return On Investment
-9.0%

For what price can you sell your share?

Current Price per Share
₩10,310.00
Expected price per share
₩9,443 - ₩11,600
How sure are you?
50%

1. Valuation of Jeil Pharm (5 min.)




Live pricePrice per Share (EOD)

₩10,310.00

Intrinsic Value Per Share

₩28,379.28 - ₩34,832.69

Total Value Per Share

₩54,578.40 - ₩61,031.82

2. Growth of Jeil Pharm (5 min.)




Is Jeil Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$281.5m$331.8m-$32.5m-10.9%

How much money is Jeil Pharm making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$13m$10.2m358.8%
Net Profit Margin-2.0%-9.8%--

How much money comes from the company's main activities?

3. Financial Health of Jeil Pharm (5 min.)




What can you expect buying and holding a share of Jeil Pharm? (5 min.)

Welcome investor! Jeil Pharm's management wants to use your money to grow the business. In return you get a share of Jeil Pharm.

What can you expect buying and holding a share of Jeil Pharm?

First you should know what it really means to hold a share of Jeil Pharm. And how you can make/lose money.

Speculation

The Price per Share of Jeil Pharm is ₩10,310. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jeil Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jeil Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩26,199.13. Based on the TTM, the Book Value Change Per Share is ₩-286.73 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-1,311.32 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩54.62 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jeil Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-1.230.0%-0.190.0%0.090.0%-0.210.0%0.710.0%
Usd Book Value Change Per Share-1.490.0%-0.200.0%-0.920.0%-0.430.0%0.650.0%
Usd Dividend Per Share0.000.0%0.040.0%0.070.0%0.060.0%0.050.0%
Usd Total Gains Per Share-1.490.0%-0.160.0%-0.850.0%-0.370.0%0.710.0%
Usd Price Per Share8.24-7.97-8.90-11.28-13.01-
Price to Earnings Ratio-1.67--26.96--9.08-13.60-21.52-
Price-to-Total Gains Ratio-5.53--0.42-29.61-49.70-42.11-
Price to Book Ratio0.45-0.41-0.42-0.50-0.87-
Price-to-Total Gains Ratio-5.53--0.42-29.61-49.70-42.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.217
Number of shares138
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.040.06
Usd Book Value Change Per Share-0.20-0.43
Usd Total Gains Per Share-0.16-0.37
Gains per Quarter (138 shares)-22.42-51.15
Gains per Year (138 shares)-89.69-204.60
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
121-111-10031-236-215
242-222-19062-472-420
363-332-28094-708-625
484-443-370125-943-830
5106-554-460156-1179-1035
6127-665-550187-1415-1240
7148-776-640219-1651-1445
8169-886-730250-1887-1650
9190-997-820281-2123-1855
10211-1108-910312-2358-2060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%7.05.00.058.3%14.06.00.070.0%21.07.00.075.0%21.07.00.075.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%12.08.00.060.0%18.010.00.064.3%18.010.00.064.3%
Dividend per Share3.00.01.075.0%11.00.01.091.7%17.00.03.085.0%25.00.03.089.3%25.00.03.089.3%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%13.07.00.065.0%19.09.00.067.9%19.09.00.067.9%

Fundamentals of Jeil Pharm

About Jeil Pharm

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 18:15:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Jeil Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jeil Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -13.3% means that ₩-0.13 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jeil Pharm:

  • The MRQ is -13.3%. The company is making a huge loss. -2
  • The TTM is -2.0%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-13.3%TTM-2.0%-11.3%
TTM-2.0%YOY-9.8%+7.8%
TTM-2.0%5Y-4.7%+2.7%
5Y-4.7%10Y196.0%-200.7%
1.1.2. Return on Assets

Shows how efficient Jeil Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -3.1% Return on Assets means that Jeil Pharm generated ₩-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jeil Pharm:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-0.5%-2.6%
TTM-0.5%YOY-2.2%+1.7%
TTM-0.5%5Y-1.0%+0.5%
5Y-1.0%10Y8.7%-9.7%
1.1.3. Return on Equity

Shows how efficient Jeil Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -8.5% Return on Equity means Jeil Pharm generated ₩-0.08 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jeil Pharm:

  • The MRQ is -8.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.5%TTM-1.3%-7.1%
TTM-1.3%YOY-5.5%+4.2%
TTM-1.3%5Y-2.4%+1.1%
5Y-2.4%10Y6.0%-8.4%

1.2. Operating Efficiency of Jeil Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jeil Pharm is operating .

  • Measures how much profit Jeil Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jeil Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.3%-2.3%
TTM2.3%YOY-0.5%+2.8%
TTM2.3%5Y-1.2%+3.6%
5Y-1.2%10Y0.7%-2.0%
1.2.2. Operating Ratio

Measures how efficient Jeil Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.72 means that the operating costs are ₩1.72 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Jeil Pharm:

  • The MRQ is 1.723. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.708. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.723TTM1.708+0.015
TTM1.708YOY1.782-0.074
TTM1.7085Y1.738-0.030
5Y1.73810Y1.630+0.108

1.3. Liquidity of Jeil Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jeil Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.93 means the company has ₩0.93 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Jeil Pharm:

  • The MRQ is 0.932. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.973. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.932TTM0.973-0.041
TTM0.973YOY1.021-0.048
TTM0.9735Y1.076-0.103
5Y1.07610Y1.310-0.234
1.3.2. Quick Ratio

Measures if Jeil Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.49 means the company can pay off ₩0.49 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jeil Pharm:

  • The MRQ is 0.486. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.495. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.486TTM0.495-0.009
TTM0.495YOY0.580-0.085
TTM0.4955Y0.593-0.098
5Y0.59310Y0.722-0.128

1.4. Solvency of Jeil Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jeil Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jeil Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.54 means that Jeil Pharm assets are financed with 54.3% credit (debt) and the remaining percentage (100% - 54.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jeil Pharm:

  • The MRQ is 0.543. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.524. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.543TTM0.524+0.019
TTM0.524YOY0.472+0.052
TTM0.5245Y0.446+0.078
5Y0.44610Y0.390+0.056
1.4.2. Debt to Equity Ratio

Measures if Jeil Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 149.6% means that company has ₩1.50 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jeil Pharm:

  • The MRQ is 1.496. The company is able to pay all its debts with equity. +1
  • The TTM is 1.385. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.496TTM1.385+0.111
TTM1.385YOY1.093+0.292
TTM1.3855Y1.014+0.371
5Y1.01410Y0.846+0.168

2. Market Valuation of Jeil Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Jeil Pharm generates.

  • Above 15 is considered overpriced but always compare Jeil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -1.67 means the investor is paying ₩-1.67 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jeil Pharm:

  • The EOD is -1.462. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.669. Based on the earnings, the company is expensive. -2
  • The TTM is -26.961. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.462MRQ-1.669+0.207
MRQ-1.669TTM-26.961+25.292
TTM-26.961YOY-9.076-17.885
TTM-26.9615Y13.595-40.556
5Y13.59510Y21.524-7.929
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jeil Pharm:

  • The EOD is 3.713. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.238. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.101. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD3.713MRQ4.238-0.526
MRQ4.238TTM1.101+3.137
TTM1.101YOY-25.132+26.233
TTM1.1015Y0.957+0.145
5Y0.95710Y39.080-38.123
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jeil Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.45 means the investor is paying ₩0.45 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Jeil Pharm:

  • The EOD is 0.394. Based on the equity, the company is cheap. +2
  • The MRQ is 0.449. Based on the equity, the company is cheap. +2
  • The TTM is 0.409. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.394MRQ0.449-0.056
MRQ0.449TTM0.409+0.040
TTM0.409YOY0.417-0.008
TTM0.4095Y0.497-0.088
5Y0.49710Y0.869-0.371
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Jeil Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2127.878-286.728-87%-1311.325-38%-610.350-71%935.683-327%
Book Value Per Share--26199.12727849.784-6%30881.968-15%32153.961-19%27588.983-5%
Current Ratio--0.9320.973-4%1.021-9%1.076-13%1.310-29%
Debt To Asset Ratio--0.5430.524+4%0.472+15%0.446+22%0.390+39%
Debt To Equity Ratio--1.4961.385+8%1.093+37%1.014+48%0.846+77%
Dividend Per Share---54.617-100%96.760-100%80.836-100%74.147-100%
Eps---1762.670-264.634-85%127.335-1484%-296.860-83%1011.431-274%
Free Cash Flow Per Share--694.255-232.104+133%-687.445+199%-251.383+136%-239.224+134%
Free Cash Flow To Equity Per Share--694.255199.774+248%-130.487+119%-25.057+104%47.779+1353%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--34832.695--------
Intrinsic Value_10Y_min--28379.278--------
Intrinsic Value_1Y_max---736.252--------
Intrinsic Value_1Y_min---725.662--------
Intrinsic Value_3Y_max--1009.121--------
Intrinsic Value_3Y_min--898.360--------
Intrinsic Value_5Y_max--6638.068--------
Intrinsic Value_5Y_min--5884.036--------
Market Cap158269841000.000-14%180682741250.000174695802500.000+3%195151176562.500-7%247283520625.000-27%285322397541.320-37%
Net Profit Margin---0.133-0.020-85%-0.098-26%-0.047-65%1.960-107%
Operating Margin---0.023-100%-0.0050%-0.0120%0.007-100%
Operating Ratio--1.7231.708+1%1.782-3%1.738-1%1.630+6%
Pb Ratio0.394-14%0.4490.409+10%0.417+8%0.497-10%0.869-48%
Pe Ratio-1.462+12%-1.669-26.961+1515%-9.076+444%13.595-112%21.524-108%
Price Per Share10310.000-14%11770.00011380.000+3%12712.500-7%16108.500-27%18586.431-37%
Price To Free Cash Flow Ratio3.713-14%4.2381.101+285%-25.132+693%0.957+343%39.080-89%
Price To Total Gains Ratio-4.845+12%-5.531-0.415-92%29.612-119%49.695-111%42.107-113%
Quick Ratio--0.4860.495-2%0.580-16%0.593-18%0.722-33%
Return On Assets---0.031-0.005-85%-0.022-30%-0.010-67%0.087-135%
Return On Equity---0.085-0.013-84%-0.055-35%-0.024-71%0.060-241%
Total Gains Per Share---2127.878-232.111-89%-1214.564-43%-529.515-75%1009.830-311%
Usd Book Value--281530247.866299267863.615-6%331851064.790-15%345519528.091-19%296465191.502-5%
Usd Book Value Change Per Share---1.490-0.201-87%-0.918-38%-0.427-71%0.655-327%
Usd Book Value Per Share--18.33919.495-6%21.617-15%22.508-19%19.312-5%
Usd Dividend Per Share---0.038-100%0.068-100%0.057-100%0.052-100%
Usd Eps---1.234-0.185-85%0.089-1484%-0.208-83%0.708-274%
Usd Free Cash Flow--7460315.331-2494145.183+133%-7387133.912+199%-2701312.109+136%-2570649.511+134%
Usd Free Cash Flow Per Share--0.486-0.162+133%-0.481+199%-0.176+136%-0.167+134%
Usd Free Cash Flow To Equity Per Share--0.4860.140+248%-0.091+119%-0.018+104%0.033+1353%
Usd Market Cap110788888.700-14%126477918.875122287061.750+3%136605823.594-7%173098464.438-27%199725678.279-37%
Usd Price Per Share7.217-14%8.2397.966+3%8.899-7%11.276-27%13.011-37%
Usd Profit---18941282.290-2843705.240-85%-13047253.662-31%-6073109.394-68%8809229.309-315%
Usd Revenue--142051820.687140707525.301+1%138768828.319+2%134481914.912+6%104517525.189+36%
Usd Total Gains Per Share---1.490-0.162-89%-0.850-43%-0.371-75%0.707-311%
 EOD+4 -4MRQTTM+9 -26YOY+8 -265Y+10 -2410Y+10 -25

3.2. Fundamental Score

Let's check the fundamental score of Jeil Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.462
Price to Book Ratio (EOD)Between0-10.394
Net Profit Margin (MRQ)Greater than0-0.133
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.486
Current Ratio (MRQ)Greater than10.932
Debt to Asset Ratio (MRQ)Less than10.543
Debt to Equity Ratio (MRQ)Less than11.496
Return on Equity (MRQ)Greater than0.15-0.085
Return on Assets (MRQ)Greater than0.05-0.031
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Jeil Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.014
Ma 20Greater thanMa 5010,636.500
Ma 50Greater thanMa 10010,744.200
Ma 100Greater thanMa 20011,145.100
OpenGreater thanClose10,240.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets879,996,991
Total Liabilities477,810,922
Total Stockholder Equity319,461,151
 As reported
Total Liabilities 477,810,922
Total Stockholder Equity+ 319,461,151
Total Assets = 879,996,991

Assets

Total Assets879,996,991
Total Current Assets384,527,207
Long-term Assets495,469,784
Total Current Assets
Cash And Cash Equivalents 37,038,628
Short-term Investments 22,092,358
Net Receivables 178,437,277
Inventory 125,280,103
Other Current Assets 4,398,229
Total Current Assets  (as reported)384,527,207
Total Current Assets  (calculated)367,246,594
+/- 17,280,612
Long-term Assets
Property Plant Equipment 228,862,356
Goodwill 44,862,269
Intangible Assets 13,093,230
Long-term Assets  (as reported)495,469,784
Long-term Assets  (calculated)286,817,855
+/- 208,651,929

Liabilities & Shareholders' Equity

Total Current Liabilities412,635,829
Long-term Liabilities65,175,094
Total Stockholder Equity319,461,151
Total Current Liabilities
Short Long Term Debt 146,829,588
Accounts payable 154,050,034
Other Current Liabilities 17,426,204
Total Current Liabilities  (as reported)412,635,829
Total Current Liabilities  (calculated)318,305,826
+/- 94,330,003
Long-term Liabilities
Long term Debt 10,500,000
Capital Lease Obligations Min Short Term Debt1,905,621
Long-term Liabilities  (as reported)65,175,094
Long-term Liabilities  (calculated)12,405,621
+/- 52,769,473
Total Stockholder Equity
Retained Earnings 79,118,791
Total Stockholder Equity (as reported)319,461,151
Total Stockholder Equity (calculated)79,118,791
+/- 240,342,360
Other
Capital Stock7,986,678
Common Stock Shares Outstanding 15,351
Net Debt 120,290,960
Net Invested Capital 476,790,739
Net Working Capital -28,108,622
Property Plant and Equipment Gross 381,322,293



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
485,736,418
199,617,806
202,623,123
197,587,508
202,738,876
299,210,970
345,745,604
920,085,825
904,784,098
909,048,815
896,638,579
846,474,534
844,764,776
870,394,926
878,368,936
887,395,067
893,146,586
899,184,129
908,098,711
892,421,378
898,925,373
906,125,668
916,332,065
865,677,012
890,866,866
901,933,555
919,359,752
879,996,991
879,996,991919,359,752901,933,555890,866,866865,677,012916,332,065906,125,668898,925,373892,421,378908,098,711899,184,129893,146,586887,395,067878,368,936870,394,926844,764,776846,474,534896,638,579909,048,815904,784,098920,085,825345,745,604299,210,970202,738,876197,587,508202,623,123199,617,806485,736,418
   > Total Current Assets 
309,663,493
37,880,897
39,669,739
38,523,418
43,500,074
44,518,440
45,079,887
337,927,936
325,161,573
330,066,425
317,922,032
313,620,339
313,776,310
336,780,168
340,526,229
335,074,174
373,483,168
373,288,320
373,717,111
335,143,722
339,897,595
347,493,881
345,659,808
352,916,444
380,718,139
389,399,683
405,751,591
384,527,207
384,527,207405,751,591389,399,683380,718,139352,916,444345,659,808347,493,881339,897,595335,143,722373,717,111373,288,320373,483,168335,074,174340,526,229336,780,168313,776,310313,620,339317,922,032330,066,425325,161,573337,927,93645,079,88744,518,44043,500,07438,523,41839,669,73937,880,897309,663,493
       Cash And Cash Equivalents 
29,121,950
12,959,978
12,585,271
8,753,840
10,607,489
12,511,272
11,924,046
41,098,113
24,259,505
33,643,938
24,339,236
21,236,950
18,583,603
14,989,515
13,851,720
20,183,389
40,491,829
34,141,678
43,119,019
28,580,778
30,356,956
18,108,081
20,567,099
34,759,506
33,297,337
43,044,782
34,536,574
37,038,628
37,038,62834,536,57443,044,78233,297,33734,759,50620,567,09918,108,08130,356,95628,580,77843,119,01934,141,67840,491,82920,183,38913,851,72014,989,51518,583,60321,236,95024,339,23633,643,93824,259,50541,098,11311,924,04612,511,27210,607,4898,753,84012,585,27112,959,97829,121,950
       Short-term Investments 
4,801,396
4,851,478
4,851,478
4,842,705
7,790,205
3,332,749
3,332,749
3,335,224
3,335,224
9,188,675
9,188,675
8,875,054
3,542,237
7,644,594
7,702,894
9,777,742
16,631,613
23,599,602
23,551,639
18,642,897
18,224,136
20,010,957
20,077,324
18,643,171
12,588,915
25,823,130
25,953,395
22,092,358
22,092,35825,953,39525,823,13012,588,91518,643,17120,077,32420,010,95718,224,13618,642,89723,551,63923,599,60216,631,6139,777,7427,702,8947,644,5943,542,2378,875,0549,188,6759,188,6753,335,2243,335,2243,332,7493,332,7497,790,2054,842,7054,851,4784,851,4784,801,396
       Net Receivables 
180,467,408
13,479,100
15,370,774
18,593,420
18,037,861
20,366,049
19,610,493
188,003,265
168,851,667
170,752,660
167,668,524
181,408,264
174,574,313
186,734,055
180,953,655
175,601,412
187,019,031
189,702,501
184,846,403
164,985,526
174,132,271
190,519,311
182,312,833
162,403,360
174,769,733
177,667,329
176,972,613
178,437,277
178,437,277176,972,613177,667,329174,769,733162,403,360182,312,833190,519,311174,132,271164,985,526184,846,403189,702,501187,019,031175,601,412180,953,655186,734,055174,574,313181,408,264167,668,524170,752,660168,851,667188,003,26519,610,49320,366,04918,037,86118,593,42015,370,77413,479,100180,467,408
       Inventory 
84,878,697
6,582,854
6,015,085
6,255,329
6,563,435
7,781,234
9,005,499
97,562,758
101,242,516
92,407,500
90,594,220
96,784,323
112,026,333
121,614,114
131,128,800
124,150,479
122,554,619
120,223,616
113,970,755
114,242,904
108,112,949
111,364,403
113,523,678
113,265,718
132,440,488
132,604,758
141,224,393
125,280,103
125,280,103141,224,393132,604,758132,440,488113,265,718113,523,678111,364,403108,112,949114,242,904113,970,755120,223,616122,554,619124,150,479131,128,800121,614,114112,026,33396,784,32390,594,22092,407,500101,242,51697,562,7589,005,4997,781,2346,563,4356,255,3296,015,0856,582,85484,878,697
       Other Current Assets 
10,394,042
7,487
847,131
78,124
501,084
468,741
1,192,400
7,788,721
-1
0
0
5,165,632
4,958,830
5,755,228
6,721,317
5,171,213
6,675,791
5,574,022
8,038,433
8,480,976
8,588,214
7,212,608
8,862,632
4,943,528
1
9,869,652
5,090,775
4,398,229
4,398,2295,090,7759,869,65214,943,5288,862,6327,212,6088,588,2148,480,9768,038,4335,574,0226,675,7915,171,2136,721,3175,755,2284,958,8305,165,63200-17,788,7211,192,400468,741501,08478,124847,1317,48710,394,042
   > Long-term Assets 
0
0
0
0
0
0
0
0
579,622,525
578,982,390
578,716,547
532,854,194
530,988,466
533,614,758
537,842,707
552,320,893
519,663,418
525,895,809
534,381,600
557,277,656
559,027,778
558,631,787
570,672,256
512,760,568
510,148,727
512,533,871
513,608,161
495,469,784
495,469,784513,608,161512,533,871510,148,727512,760,568570,672,256558,631,787559,027,778557,277,656534,381,600525,895,809519,663,418552,320,893537,842,707533,614,758530,988,466532,854,194578,716,547578,982,390579,622,52500000000
       Property Plant Equipment 
113,963,147
5,060,449
5,082,438
5,060,839
5,028,298
15,227,336
15,208,112
135,598,353
134,464,232
131,133,549
130,463,203
164,485,086
165,833,979
164,610,274
165,213,279
170,478,767
174,075,953
177,624,100
185,226,036
212,965,050
217,117,993
215,827,388
222,654,273
233,120,075
232,670,178
231,218,939
229,131,608
228,862,356
228,862,356229,131,608231,218,939232,670,178233,120,075222,654,273215,827,388217,117,993212,965,050185,226,036177,624,100174,075,953170,478,767165,213,279164,610,274165,833,979164,485,086130,463,203131,133,549134,464,232135,598,35315,208,11215,227,3365,028,2985,060,8395,082,4385,060,449113,963,147
       Goodwill 
0
0
0
0
0
0
0
266,347,673
266,347,673
266,347,673
266,347,673
168,815,256
168,815,256
168,815,256
168,815,256
168,815,256
168,815,256
168,815,256
168,815,256
151,801,216
151,801,216
151,801,216
151,801,216
73,465,884
73,465,884
73,465,884
73,465,884
44,862,269
44,862,26973,465,88473,465,88473,465,88473,465,884151,801,216151,801,216151,801,216151,801,216168,815,256168,815,256168,815,256168,815,256168,815,256168,815,256168,815,256168,815,256266,347,673266,347,673266,347,673266,347,6730000000
       Long Term Investments 
46,385,072
140,880,041
142,163,645
138,045,900
138,363,155
127,580,904
173,573,970
60,887,267
59,537,236
59,785,826
60,575,780
65,096,639
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000065,096,63960,575,78059,785,82659,537,23660,887,267173,573,970127,580,904138,363,155138,045,900142,163,645140,880,04146,385,072
       Intangible Assets 
4,311,625
14,688
14,546
16,184
15,608
15,112
14,457
4,372,934
4,424,361
4,398,489
4,382,264
4,350,060
4,306,508
4,463,858
4,424,925
4,117,781
4,055,834
3,900,638
3,838,197
3,781,277
3,729,827
3,749,039
8,566,270
9,472,328
10,736,616
11,758,727
12,709,366
13,093,230
13,093,23012,709,36611,758,72710,736,6169,472,3288,566,2703,749,0393,729,8273,781,2773,838,1973,900,6384,055,8344,117,7814,424,9254,463,8584,306,5084,350,0604,382,2644,398,4894,424,3614,372,93414,45715,11215,60816,18414,54614,6884,311,625
       Long-term Assets Other 
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
-1
1
0
01-100-10000000000000100000000
> Total Liabilities 
234,061,857
27,382,999
29,138,953
27,149,058
29,009,333
90,005,648
99,467,613
330,509,526
315,082,898
316,845,334
302,164,748
363,437,471
358,280,926
380,297,736
385,601,535
388,110,851
382,527,284
385,925,656
394,745,768
392,107,688
405,256,540
413,231,433
426,395,793
445,884,553
454,715,979
465,019,816
484,508,368
477,810,922
477,810,922484,508,368465,019,816454,715,979445,884,553426,395,793413,231,433405,256,540392,107,688394,745,768385,925,656382,527,284388,110,851385,601,535380,297,736358,280,926363,437,471302,164,748316,845,334315,082,898330,509,52699,467,61390,005,64829,009,33327,149,05829,138,95327,382,999234,061,857
   > Total Current Liabilities 
186,761,083
12,558,537
13,844,803
15,367,628
17,096,682
65,660,691
65,095,310
280,976,703
265,623,410
267,399,527
252,697,135
313,828,871
308,978,178
330,668,888
332,107,173
327,317,450
305,003,597
309,015,424
314,083,103
298,023,551
310,444,327
339,919,246
352,158,290
358,504,740
371,353,090
394,907,187
427,393,394
412,635,829
412,635,829427,393,394394,907,187371,353,090358,504,740352,158,290339,919,246310,444,327298,023,551314,083,103309,015,424305,003,597327,317,450332,107,173330,668,888308,978,178313,828,871252,697,135267,399,527265,623,410280,976,70365,095,31065,660,69117,096,68215,367,62813,844,80312,558,537186,761,083
       Short-term Debt 
43,571,778
779,318
1,455,035
678,579
0
47,000,000
0
5,593,750
65,625,000
67,756,250
66,525,000
108,492,875
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000108,492,87566,525,00067,756,25065,625,0005,593,750047,000,0000678,5791,455,035779,31843,571,778
       Short Long Term Debt 
43,571,778
779,318
1,455,035
678,579
0
47,000,000
0
5,593,750
65,625,000
67,756,250
66,525,000
108,492,875
104,282,345
124,615,751
134,031,447
136,634,680
104,240,359
98,777,724
104,886,932
94,157,517
98,140,610
103,860,929
119,461,735
118,395,170
132,313,826
147,575,435
157,448,801
146,829,588
146,829,588157,448,801147,575,435132,313,826118,395,170119,461,735103,860,92998,140,61094,157,517104,886,93298,777,724104,240,359136,634,680134,031,447124,615,751104,282,345108,492,87566,525,00067,756,25065,625,0005,593,750047,000,0000678,5791,455,035779,31843,571,778
       Accounts payable 
149,998,863
5,850,227
5,970,788
5,000,176
6,864,123
8,531,353
8,106,319
151,126,764
164,140,216
162,048,615
149,105,201
157,545,159
173,223,440
166,141,087
156,545,438
149,264,533
157,647,458
163,942,303
163,660,347
159,388,338
163,941,713
172,719,119
168,589,774
162,967,415
163,465,695
153,206,201
165,536,521
154,050,034
154,050,034165,536,521153,206,201163,465,695162,967,415168,589,774172,719,119163,941,713159,388,338163,660,347163,942,303157,647,458149,264,533156,545,438166,141,087173,223,440157,545,159149,105,201162,048,615164,140,216151,126,7648,106,3198,531,3536,864,1235,000,1765,970,7885,850,227149,998,863
       Other Current Liabilities 
20,190,442
5,928,992
6,418,980
9,688,873
10,232,559
10,067,513
9,872,426
34,643,263
1
1
1
47,612,738
30,520,692
38,967,897
40,676,915
40,673,856
42,389,566
45,559,435
44,602,910
43,526,182
47,274,238
62,368,904
63,215,195
17,245,828
17,393,703
93,174,820
18,324,894
17,426,204
17,426,20418,324,89493,174,82017,393,70317,245,82863,215,19562,368,90447,274,23843,526,18244,602,91045,559,43542,389,56640,673,85640,676,91538,967,89730,520,69247,612,73811134,643,2639,872,42610,067,51310,232,5599,688,8736,418,9805,928,99220,190,442
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
49,459,488
49,445,808
49,467,613
49,608,600
49,302,748
49,628,848
53,494,361
60,793,400
77,523,687
76,910,232
80,662,665
94,084,137
94,812,213
65,462,750
66,170,105
87,379,812
83,362,889
57,229,164
57,114,974
65,175,094
65,175,09457,114,97457,229,16483,362,88987,379,81266,170,10565,462,75094,812,21394,084,13780,662,66576,910,23277,523,68760,793,40053,494,36149,628,84849,302,74849,608,60049,467,61349,445,80849,459,48800000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
364,828
930,723
1,191,082
320,949
1,005,644
1,115,186
938,947
790,659
937,274
1,013,421
1,368,920
2,383,249
2,391,097
2,258,113
1,992,844
1,869,185
1,730,242
2,069,259
1,895,407
1,905,621
1,905,6211,895,4072,069,2591,730,2421,869,1851,992,8442,258,1132,391,0972,383,2491,368,9201,013,421937,274790,659938,9471,115,1861,005,644320,9491,191,082930,723364,82800000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
-1
0
0
0
-1
0
0
0
0
0000-1000-10-100000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,532,099
0
0
7,133,817
0
0
007,133,817004,532,0990000000000000000000000
> Total Stockholder Equity
248,369,356
168,546,600
65,835,606
166,735,675
169,942,539
204,958,990
241,884,869
490,333,788
490,792,112
492,864,203
494,442,406
393,481,762
395,321,155
398,613,516
401,173,432
407,451,787
412,750,284
412,136,405
412,765,491
411,730,535
408,143,731
408,311,403
407,677,046
337,764,676
346,149,756
347,832,207
348,103,290
319,461,151
319,461,151348,103,290347,832,207346,149,756337,764,676407,677,046408,311,403408,143,731411,730,535412,765,491412,136,405412,750,284407,451,787401,173,432398,613,516395,321,155393,481,762494,442,406492,864,203490,792,112490,333,788241,884,869204,958,990169,942,539166,735,67565,835,606168,546,600248,369,356
   Common Stock
7,425,000
2,172,754
2,172,754
2,172,754
2,172,754
2,172,754
2,172,754
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
7,986,678
0
0
7,986,678
0
0
007,986,678007,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6787,986,6782,172,7542,172,7542,172,7542,172,7542,172,7542,172,7547,425,000
   Retained Earnings 
226,658,521
744,651,958
642,531,115
745,147,358
233,188,800
256,325,945
258,018,691
261,231,492
261,778,104
264,347,082
266,511,401
167,825,000
170,893,251
170,727,071
172,550,654
175,785,236
175,580,594
178,081,774
179,096,990
172,151,257
168,934,053
169,556,968
169,161,268
98,244,588
107,288,130
108,546,408
108,286,262
79,118,791
79,118,791108,286,262108,546,408107,288,13098,244,588169,161,268169,556,968168,934,053172,151,257179,096,990178,081,774175,580,594175,785,236172,550,654170,727,071170,893,251167,825,000266,511,401264,347,082261,778,104261,231,492258,018,691256,325,945233,188,800745,147,358642,531,115744,651,958226,658,521
   Capital Surplus 0000000000000000000000000000
   Treasury Stock000000000000000000000-3,421,988-3,421,988-3,421,988-3,421,988-3,513,386-3,229,977-10,826,884
   Other Stockholders Equity 
20,504,113
20,633,859
20,327,118
16,529,102
18,193,369
30,422,666
65,655,799
51,222,048
-118,096,662
51,006,340
50,420,223
52,277,495
51,048,638
54,507,179
55,241,874
53,111,961
52,435,423
52,437,570
52,117,486
58,631,074
58,585,064
58,130,615
57,893,671
0
0
58,592,031
0
0
0058,592,0310057,893,67158,130,61558,585,06458,631,07452,117,48652,437,57052,435,42353,111,96155,241,87454,507,17951,048,63852,277,49550,420,22351,006,340-118,096,66251,222,04865,655,79930,422,66618,193,36916,529,10220,327,11820,633,85920,504,113



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue804,043,002
Cost of Revenue-589,458,611
Gross Profit214,584,391214,584,391
 
Operating Income (+$)
Gross Profit214,584,391
Operating Expense-783,122,816
Operating Income20,920,186-568,538,425
 
Operating Expense (+$)
Research Development46,037,531
Selling General Administrative80,545,785
Selling And Marketing Expenses0
Operating Expense783,122,816126,583,316
 
Net Interest Income (+$)
Interest Income1,731,420
Interest Expense-10,672,114
Other Finance Cost-1
Net Interest Income-8,940,693
 
Pretax Income (+$)
Operating Income20,920,186
Net Interest Income-8,940,693
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-13,981,65020,920,186
EBIT - interestExpense = -10,672,114
-16,249,744
-5,577,630
Interest Expense10,672,114
Earnings Before Interest and Taxes (EBIT)0-3,309,536
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-13,981,650
Tax Provision--740,818
Net Income From Continuing Ops-13,240,832-13,240,832
Net Income-16,249,744
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net08,940,693
 

Technical Analysis of Jeil Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jeil Pharm. The general trend of Jeil Pharm is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jeil Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jeil Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 11,310 < 11,350 < 11,600.

The bearish price targets are: 9,463 > 9,453 > 9,443.

Tweet this
Jeil Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jeil Pharm. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jeil Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jeil Pharm. The current macd is -204.3314075.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jeil Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Jeil Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Jeil Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Jeil Pharm Daily Moving Average Convergence/Divergence (MACD) ChartJeil Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jeil Pharm. The current adx is 24.11.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Jeil Pharm shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Jeil Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jeil Pharm. The current sar is 11,945.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jeil Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jeil Pharm. The current rsi is 44.01. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Jeil Pharm Daily Relative Strength Index (RSI) ChartJeil Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jeil Pharm. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Jeil Pharm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Jeil Pharm Daily Stochastic Oscillator ChartJeil Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jeil Pharm. The current cci is -78.95800003.

Jeil Pharm Daily Commodity Channel Index (CCI) ChartJeil Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jeil Pharm. The current cmo is -9.36584626.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Jeil Pharm Daily Chande Momentum Oscillator (CMO) ChartJeil Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jeil Pharm. The current willr is -79.00763359.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Jeil Pharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Jeil Pharm Daily Williams %R ChartJeil Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jeil Pharm.

Jeil Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jeil Pharm. The current atr is 466.28.

Jeil Pharm Daily Average True Range (ATR) ChartJeil Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jeil Pharm. The current obv is 25,021,050.

Jeil Pharm Daily On-Balance Volume (OBV) ChartJeil Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jeil Pharm. The current mfi is 90.78.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Jeil Pharm Daily Money Flow Index (MFI) ChartJeil Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jeil Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-27MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Jeil Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jeil Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.014
Ma 20Greater thanMa 5010,636.500
Ma 50Greater thanMa 10010,744.200
Ma 100Greater thanMa 20011,145.100
OpenGreater thanClose10,240.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jeil Pharm with someone you think should read this too:
  • Are you bullish or bearish on Jeil Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jeil Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jeil Pharm

I send you an email if I find something interesting about Jeil Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Jeil Pharm.

Receive notifications about Jeil Pharm in your mailbox!